Avsar.

Healthcare · Biotechnology

Advanced Enzyme Technologies Ltd (ADVENZYMES)

₹298.85

Mkt cap
₹3,335 Cr
P/E ratio
21.20
P/B
2.05
Div yield
1.80%
ROE
10.20%
ROCE
14.00%
EPS (TTM)
₹14.10
Book value
₹146
52W range
255–392
Sector
Healthcare

Price history

Previous close

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes. [1]

NSE ADVENZYMESBSE 540025
Health check
Mixed
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBearish
52-week range
−23.78% from high
₹299
₹255+17.06% from low₹392
Current
₹298.85
Prev close
₹296.80
Day
+0.69%
Price performance
1D
+0.69%
1W
+1.19%
1M
+1.46%
3M
−19.51%
6M
+1.22%
1Y
−12.42%
YTD
−1.09%

Financials

Revenue, profit & margin
P/E ratio
21.2×
ADVENZYMES is 61% below the sector median of 54.9×
ADVENZYMES21.2×
Sector median54.9×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales147158161158155146169167186185172203190
Expenses103107107102103104114122129124123140139
Operating Profit44515455514255465660496351
OPM %30%32%33%35%33%29%33%27%30%33%29%31%27%
Other Income7614-67108991020713
Interest1111111111111
Depreciation9999999101010101010
Profit before tax41485940494253435560586054
Tax %29%27%28%25%28%21%27%38%26%25%26%24%28%
Net Profit29354230353339274045434539
EPS in Rs2.583.083.742.533.052.943.372.373.573.873.803.843.31
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

No reaction history yet.
No quarterly filings ingested yet.

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

as of Jun 2026
43.25%Promoter
Promoters43.25%
FIIs26.70%1.20
DIIs4.77%0.64
Public25.28%0.57
Ownership trend

Peers

6 companies
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
ANTHEM₹933.5088.6352,5880.21%120−11.67%418−22.58%30.37%
ADVENZYMES₹297.8521.163,3351.80%39−7.11%190+2.09%13.96%
CCME₹29.26—1320.00%0−116.67%0—−2.92%
VIVOBIOT₹18.99—420.00%0−85.82%14+14.15%7.29%
SHREEGANES₹0.51—200.00%−1−272.73%1+3.62%0.80%
GVBL₹29.88913.0090.00%0−50.00%0−55.56%1.02%
Median: 3 Co.₹297.8554.893,3350.21%39−11.67%190−10.24%13.96%

Filings

Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts100
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMar 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025PPTSep 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024
Credit ratings6
Rating update 30 AprcrisilRating update 13 FebicraRating update 30 Jan 2025crisilRating update 28 Dec 2023crisilRating update 31 Oct 2022crisilRating update 18 Aug 2021crisil
Announcements5
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 7 Sep - On September 07, 2026, company bought 31,197 shares; cumulative buyback reached 10,59,985 shares at ₹295.9121.Disclosure Under Regulation 31A Of The SEBI (LODR) Regulations, 2015 (As Amended) 5 Sep - Five promoter group members requested reclassification to public; all hold nil shares.Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares 4 SepAnnouncement under Regulation 30 (LODR)-Daily Buy Back of equity shares 3 SepAnnouncement under Regulation 30 (LODR)-Daily Buy Back of equity shares 2 Sep